Enteric Disease Testing Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

 

Enteric Disease Testing Market

Salmonellosis, shigellosis, giardiasis, campylobacteriosis, cryptosporidiosis, and cholera are examples of Enteric Diseases, which are intestinal infections brought on by a range of bacteria, viruses, and parasites when they enter the body through the mouth or digestive tracts.

According To Coherent Market Insights, The Global Enteric Disease Testing Market Is Estimated To Account For US$ 4,432.7 Mn In Terms Of Value By The End Of 2027.

According to a number of epidemiological sources, including the WHO, CDC, and NCBI, developing nations are responsible for around 85% of the global incidence of enteric diseases. However, because of a lack of awareness, inadequate laboratory conditions, and deplorable economic situations in these areas, a sizable population who suffers from numerous intestinal diseases lacks access to basic diagnostic facilities.

Rapid dipstick tests that are affordable and easy to use are anticipated to develop significantly throughout the projection period since they do not require a laboratory environment for diagnosis and may be completed by patients. Enteric Disease Testing Market demand for more modern technology-based laboratory tests, such EIA and PCR testing, may expand in nations with more developed economies, like India, China, Mexico, and Brazil.

The global burden of enteric illness infection can have a significant impact on health care costs and potentially result in fatalities. One of the enteric infections, typhoid salmonellosis, alone causes 16 million new cases and almost 600,000 fatalities each year. The only method to manage this load is by early diagnosis of intestinal illnesses. Assays that may quickly diagnose sickness, like enzyme immunoassay (EIA), PCR-based testing, and dipstick-based tests, are replacing labor- and time-intensive traditional culture procedures. One of the key reasons propelling the Enteric Disease Testing Market is the rise in demand for quick diagnostic tests.

Molecular diagnostic methods like multiplexed assays are more recent in the field of medicine than singleplex assays. Equipment for multiplexed assays is therefore rather pricey. Compared to singleplex assay tests, multiplexed assay tests are less expensive per test, although initial instrument installation costs are greater.

Larger hospitals, research centres, and other healthcare providers can readily afford multiplex diagnostic devices when you include in the original investment and ongoing maintenance costs. On the other hand, it can be challenging for smaller healthcare organisations and institutes to purchase multiplexed assay equipment. This limits the use of molecular diagnostic tools for Enteric Disease Testing Market.

Additionally, the high cost of this technology restricts market expansion, particularly in developing countries. Because of this, it is anticipated that the technology's high price will be a major barrier until local companies introduce comparable technologies at a lower price.

Major Companies Involved are- Alere, Inc., Becton Dickinson & Company, Biomerica, Inc., bioMerieux, Bio-Rad, Cepheid, Coris BioConcept, DiaSorin, Meridian Bioscience, Inc., Quest Diagnostics, and Trinity Biotech

Comments

Popular posts from this blog

Forging has significant application in creation of various metal for wide range of applications

Ginseng Market Outlook, Analysis and forecast up to 2028

The Vaccine Contract Manufacturing Industry to Flourish Due to Urgent Need to Develop Reliable and Cost-Effective Vaccines against Covid-19